109926-35-4

Usage

Uses

Used in Pharmaceutical Industry:
2,3-DIHYDRO-BENZOFURAN-3-YLAMINE is used as a building block for the synthesis of various pharmaceuticals and biologically active compounds due to its versatile chemical structure and potential therapeutic properties.
Used in Research and Development:
2,3-DIHYDRO-BENZOFURAN-3-YLAMINE is used as a research tool in the development of new drugs, aiding in the discovery and optimization of pharmaceutical agents with improved efficacy and safety profiles.
Used in Neurological Disorders Treatment:
2,3-DIHYDRO-BENZOFURAN-3-YLAMINE is used as a potential therapeutic agent for neurological disorders, leveraging its role as a serotonin reuptake inhibitor to modulate neurotransmission and alleviate symptoms.
Used in Synthesis of Complex Organic Molecules:
2,3-DIHYDRO-BENZOFURAN-3-YLAMINE is used as a starting material for the synthesis of other complex organic molecules, contributing to the advancement of organic chemistry and the creation of novel chemical entities with diverse applications.

InChI:InChI=1/C8H9NO/c9-7-5-10-8-4-2-1-3-6(7)8/h1-4,7H,5,9H2

Upstream product

• 82415-84-7 3(2H)-benzofuranone oxime 
• 75420-78-9 3-nitrobenzofuran 
• 60-29-7 diethyl ether 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 271-89-6 1-benzofurane 
• 1410747-74-8 tert-butyl (2,3-dihydrobenzofuran-3-yl)carbamate 
• 6280-80-4 2-Formylphenoxyacetic acid 
• 82415-84-7 benzofuran-3(2H)-one oxime 

Downstream Products

• 1032279-06-3 rac-N-[2-(2,3-Dihydro-benzofuran-3-ylamino)-quinolin-5-yl]-3,4,5-trifluoro-benzenesulfonamide 
• 1410747-77-1 tert-butyl benzyl(2,3-dihydrobenzofuran-3-yl)carbamate 
• 1410747-83-9 methyl benzyl(2,3-dihydrobenzofuran-3-yl)carbamate 
• 1410748-15-0 N-benzyl-2,3-dihydrobenzofuran-3-amine 

Relevant academic research and scientific papers

ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor

ERK INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

Titania-promoted carboxylic acid alkylations of alkenes and cascade addition-cyclizations

Photochemical reactions employing TiO2 and carboxylic acids under dry anaerobic conditions led to several types of C-C bond-forming processes with electron-deficient alkenes. The efficiency of alkylation varied appreciably with substituents in the carboxylic acids. The reactions of aryloxyacetic acids with maleimides resulted in a cascade process in which a pyrrolochromene derivative accompanied the alkylated succinimide. The selectivity for one or other of these products could be tuned to some extent by employing the photoredox catalyst under different conditions. Aryloxyacetic acids adapted for intramolecular ring closures by inclusion of 2-alkenyl, 2-aryl, or 2-oximinyl functionality reacted rather poorly. Profiles of reactant consumption and product formation for these systems were obtained by an in situ NMR monitoring technique. An array of different catalyst forms were tested for efficiency and ease of use. The proposed mechanism, involving hole capture at the TiO2 surface by the carboxylates followed by CO2 loss, was supported by EPR spectroscopic evidence of the intermediates. Deuterium labeling indicated that the titania likely donates protons from surface hydroxyl groups as well as supplying electrons and holes, thus acting as both a catalyst and a reaction partner.

Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans and its application to the formal total synthesis of (-)-quinocarcinamide

An unusual Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans is described. The fused tricyclic ring system is the key structural element for this reaction as it restricts C-N bond rotation and/or destabilizes the benzofuran ring. We achieved the formal total synthesis of (-)-quinocarcinamide using a combination of this reaction and the Au(I)-catalyzed 6-endo-dig hydroamination of an alkyne.

Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans and its application to the formal total synthesis of (-)-quinocarcinamide

An unusual Lewis-acid-mediated ring-exchange reaction of dihydrobenzofurans is described. The fused tricyclic ring system is the key structural element for this reaction as it restricts C-N bond rotation and/or destabilizes the benzofuran ring. We achieved the formal total synthesis of (-)-quinocarcinamide using a combination of this reaction and the Au(I)-catalyzed 6-endo-dig hydroamination of an alkyne.

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).

Q.S.A.R. DE DERIVES DE DIHYDRO-2,3 BENZOFURANNAMINE-3 INHIBITEURS DE CROISSANCE VEGETALE

A series of N-(aminoacetyl)-2,3-dihydro-3-benzofurannamine were synthetized and tested by means of the growth inhibition technical using Lepidium Sativum L. root meristem.Simultaneous applications of Fujita-Ban, Hansch methods and molecular connectivity have shown the preponderant role of lipophilicity and of pKa determined experimentally.